Portfolio – Open Trials

Assessing the DNA methylation inhibitory effects of 5-azacytidine on cardiac relevant genes: a pilot study

An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1

Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer

A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer

CV6-168 – A First in Human Modular, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of the specific dUTPase inhibitor CV6-168 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies

Developing ctDNA guided adjuvant therapy for gastrooesophageal cancer.
A single arm phase II trial of trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma cancer who are ctDNA and HER2 positive

Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly-defined Indications using a National Evaluation platform trial

Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women

Feasibility of a co-designed lifestyle intervention during treatment for advanced colorectal cancer: a single centre pilot.

An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost
radiotherapy against a standard 3-week schedule in patients with early breast cancer

A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer

Investigation of Circulating Haematological Biomarkers in Cancer